NEW YORK, Feb. 08, 2023 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc. [Read more…]
Immunotherapy company iPSirius appoints Dr. Stephen Sullivan as Chief Operating Officer
iPSirius appoints COO to oversee human trials with allogeneic cancer vaccines made from stem cells
Paris, France, 10th February 2023 – iPSirius, a pre-clinical biotech company in the immuno-oncology field, is pleased to announce the appointment of a new COO, Dr. Stephen Sullivan. Dr. Sullivan, previously the program manager at the Global Alliance for iPSC therapies, is a pluripotent stem cell manufacturing expert. He will oversee the day-to-day operations of the company and the first in-human trials for the company’snovel therapeutic, IPVAC. [Read more…]
The Crowley Center for Regenerative & Biotherapeutics Names New Scientific Officer
Dr. Michael Heke, Ph.D. will drive integration of exosome-based topical cosmetics, regenerative biotherapeutics medical and scientific intelligence, and as well as aspects of patient safety as Managing Director-Scientific Officer.
Rochester, NY, February 8, 2023 — The Crowley Center™ for Regenerative & Biotherapeutics, LLC (aka AT Venture Center™, LLC) today announced that Dr. Heke has been appointed as Chief Scientific Officer of The Crowley Center, and its subsidiaries, Regenerelle™ Cellular & Exosome Biotherapeutics, Resiliélle™ Exosome Cosmetics, Sanatela® Regenerative Medical, Sanatela® AT Medical Solutions, Sanatela® Precision Cancer Diagnostics, Sanatela® Animal Biotechnologies, Sanatela® Biotechnologies, Sanatela® Matrix, Sanatela® Life Sciences and AT Venture Center for Global Techtrepreneurship™. Regenerelle’s and Sanatela’s IP technologies are both Patent Pending. [Read more…]
Creative Bioarray Releases a Wide Range of iPSC Differentiation Kits to Support iPS Cell Differentiation
Creative Bioarray announced the release of its wide range of iPSC differentiation kits to support iPS cell differentiation.
New York, USA, January 31, 2023 – Creative Bioarray, one of the world’s leading biotechnology products and services providers, is dedicated to becoming a profitable premier provider of quality life science research reagents and services helping customers develop innovative methods and products. [Read more…]
Colossal Biosciences Secures $150M Series B and Announces Plan to De-Extinct the Iconic Dodo
Following massive progress on the Woolly Mammoth and Tasmanian tiger, Colossal launches Avian Genomics Group to continue groundbreaking de-extinction pursuits
Colossal Biosciences, the world’s first de-extinction company, has announced an oversubscribed $150M Series B financing led by United States Innovative Technology Fund (“USIT”), with participation from Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, and Jazz Ventures, among others. [Read more…]
- « Previous Page
- 1
- …
- 125
- 126
- 127
- 128
- 129
- …
- 334
- Next Page »